CVM

CEL-SCI Corporation (CEL-SCI) - 10-K Summary

Business Context and Reporting Period

Company: CEL-SCI Corporation
Filing Type: Annual Report (Form 10-K)
Period Ended: September 30, 2002
Business Overview: CEL-SCI is a biotechnology company focused on the research and development of immunotherapies, primarily MULTIKINE (a cytokine cocktail for cancer treatment) and the L.E.A.P.S. technology (T-cell modulation for vaccines). The company has no commercial product sales and relies on grants, equity financing, and debt to fund operations.

Key Financial Metrics (Fiscal Year 2002)

Material Changes vs. Prior Period

• Expense Reduction: Operating expenses decreased significantly from $11.4M in 2001 to $6.7M in 2002. This was driven by a cost-reduction program, workforce reduction, and the completion of the MULTIKINE production run in Q1 2002.
• Interest Expense: Interest expense increased to $2.1M in 2002 (from $0 in prior years) due to the issuance of Series F and Series G convertible notes. This includes the amortization of discounts related to warrants and beneficial conversion features.
• Stock-Based Compensation Reversal: General and administrative expenses included a reversal of $593,472 in compensation charges due to a decline in the intrinsic value of repriced employee options.
• Liquidity: Working capital declined from $2.8M to $0.7M. Cash balances increased slightly to $2.1M, supported by proceeds from an equity line of credit and convertible debt conversions.

Outlook, Risks, and Management Commentary

• Capital Requirements: The company has no revenue from product sales and expects to continue incurring losses. Management anticipates spending significantly less on R&D in fiscal 2003 due to the completion of manufacturing validation but warns that substantial additional funds are needed for extensive clinical trials required for FDA approval.
• Financing Strategy: Future funding is expected to come from the equity line of credit with Paul Revere Capital Partners (up to $10M available), issuance of convertible debt, and further equity sales. There is no assurance that financing will be available on favorable terms.
• Regulatory Risks: Commercialization is years away. The company faces significant risk regarding FDA approval of MULTIKINE and other products. Clinical trials conducted outside the U.S. may not be accepted by the FDA.
• Debt Covenants: Convertible notes contain restrictive covenants, including limitations on dividends, stock purchases, and further equity sales (with exceptions for permitted financings). Failure to meet covenants or maintain listing status could trigger redemption of notes at 130% of principal.
• Dilution: Significant dilution is expected due to the conversion of outstanding preferred stock, convertible notes, and the exercise of numerous warrants and options. As of Nov 30, 2002, over 44.8M shares were outstanding, with millions more issuable upon conversion/exercise.

Investor Verification Checklist

• Cash Runway: Verify if current cash ($2.1M) and the equity line of credit are sufficient to fund operations through the next fiscal year given the high burn rate.
• Debt Conversion Terms: Review the specific conversion prices and anti-dilution provisions of the Series F and Series G notes, as well as the Cambrex promissory note, to assess potential dilution impact.
• Clinical Trial Status: Confirm the current status and results of the Phase II head and neck cancer study and the Phase I cervical dysplasia study, as these are critical for future valuation.
• Equity Line Utilization: Monitor the utilization of the $10M equity line with Paul Revere Capital Partners and the discount rate (11%) applied to share sales.
• Preferred Stock Conversion: Track the automatic conversion date (August 2003) for Series E Preferred Stock, which could result in a 200% conversion ratio and significant dilution.